Health
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases - - Data to be presented in a poster session at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, California on Monday April 20, 2026- ROCKVILLE, Md., April 17, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologic
About this update from Theriva Biologics, Inc.
[{"type":"image","alt":"Theriva Biologics, Inc.","displaySize":"","headline":null,"caption":"Theriva Biologics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/66da9d5d384dea69bc442e7797b7b48a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/w6l7LiiIpHHO9ctC0BljZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Mw--/https://media.zenfs.com/en/globenewswire.com/66da9d5d384dea69bc442e7797b7b48a","width":300,"height":102}},"lazy":false},{"type":"text","content":"- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases -","length":268,"tagName":"p"},{"type":"text","content":"- Data to be presented in a poster session at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, California on Monday April 20, 2026-","length":162,"tagName":"p"},{"type":"text","content":"ROCKVILLE, Md., April 17, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced an upcoming poster presentation of new data and subgroup analyses from the VIRAGE Phase 2b clinical trial evaluating VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel in newly-diagnosed metastatic pancreatic cancer patients. Tumor reponse, biomarker data, and subgroup analyses are to be presented at the American Association for Cancer Research (AACR) Annual Meeting to be held in San Diego, CA from 17-22 April 2026.","length":716,"tagName":"p"},{"type":"text","content":"Details of the poster presentation are below:","length":45,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Presenting author: Dr. Manuel Hidalgo, NYU Langone Health Perlmutter Cancer Center, New York, NY","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"Title: Analysis of tumor and biomarker responses in the VIRAGE Trial, a randomized Phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC)",...